Interleukin-18 as a Therapeutic Target in Acute Myocardial Infarction and Heart Failure
Abstract Interleukin 18 (IL-18) is a proinflammatory cytokine in the IL-1 family that has been implicated in a number of disease states. In animal models of acute myocardial infarction (AMI), pressure overload, and LPS-induced dysfunction, IL-18 regulates cardiomyocyte hypertrophy and induces cardiac contractile dysfunction and extracellular matrix remodeling. In patients, high IL-18 levels correlate with increased risk of developing cardiovascular disease (CVD) and with a worse prognosis in patients with established CVD. Two strategies have been used to counter the effects of IL-18:IL-18 binding protein (IL-18BP), a naturally occurring protein, and a neutralizing IL-18 antibody. Recombinant human IL-18BP (r-hIL-18BP) has been investigated in animal studies and in phase I/II clinical trials for psoriasis and rheumatoid arthritis. A phase II clinical trial using a humanized monoclonal IL-18 antibody for type 2 diabetes is ongoing. Here we review the literature regarding the role of IL-18 in AMI and heart failure and the evidence and challenges of using IL-18BP and blocking IL-18 antibodies as a therapeutic strategy in patients with heart disease..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Molecular medicine - 20(2014), 1 vom: Jan., Seite 221-229 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
O’Brien, Laura C. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© The Author(s) 2014 |
|---|
| doi: |
10.2119/molmed.2014.00034 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2051587795 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2051587795 | ||
| 003 | DE-627 | ||
| 005 | 20230511145652.0 | ||
| 007 | tu | ||
| 008 | 200819s2014 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.2119/molmed.2014.00034 |2 doi | |
| 035 | |a (DE-627)OLC2051587795 | ||
| 035 | |a (DE-He213)molmed.2014.00034-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a O’Brien, Laura C. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interleukin-18 as a Therapeutic Target in Acute Myocardial Infarction and Heart Failure |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2014 | ||
| 520 | |a Abstract Interleukin 18 (IL-18) is a proinflammatory cytokine in the IL-1 family that has been implicated in a number of disease states. In animal models of acute myocardial infarction (AMI), pressure overload, and LPS-induced dysfunction, IL-18 regulates cardiomyocyte hypertrophy and induces cardiac contractile dysfunction and extracellular matrix remodeling. In patients, high IL-18 levels correlate with increased risk of developing cardiovascular disease (CVD) and with a worse prognosis in patients with established CVD. Two strategies have been used to counter the effects of IL-18:IL-18 binding protein (IL-18BP), a naturally occurring protein, and a neutralizing IL-18 antibody. Recombinant human IL-18BP (r-hIL-18BP) has been investigated in animal studies and in phase I/II clinical trials for psoriasis and rheumatoid arthritis. A phase II clinical trial using a humanized monoclonal IL-18 antibody for type 2 diabetes is ongoing. Here we review the literature regarding the role of IL-18 in AMI and heart failure and the evidence and challenges of using IL-18BP and blocking IL-18 antibodies as a therapeutic strategy in patients with heart disease. | ||
| 700 | 1 | |a Mezzaroma, Eleonora |4 aut | |
| 700 | 1 | |a Van Tassell, Benjamin W. |4 aut | |
| 700 | 1 | |a Marchetti, Carlo |4 aut | |
| 700 | 1 | |a Carbone, Salvatore |4 aut | |
| 700 | 1 | |a Abbate, Antonio |4 aut | |
| 700 | 1 | |a Toldo, Stefano |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular medicine |d BioMed Central, 1994 |g 20(2014), 1 vom: Jan., Seite 221-229 |w (DE-627)188851313 |w (DE-600)1283676-X |w (DE-576)055401635 |x 1076-1551 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2014 |g number:1 |g month:01 |g pages:221-229 |
| 856 | 4 | 1 | |u https://doi.org/10.2119/molmed.2014.00034 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 20 |j 2014 |e 1 |c 01 |h 221-229 | ||